YOUR BUSINESS AUTHORITY
Springfield, MO
Pfizer is stopping development of a new daily weight loss pill.
A patient in the drug trial reportedly experienced a liver injury.
"While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients," said Dr. Chris Boshoff, Pfizer's chief scientific officer.
Read more from CNBC.
Project work in Springfield corridor will continue into 2031.
Thanksgiving staple recalled at Costco
Warren Buffett donates $5.5B worth of Berkshire Hathaway shares
HBA of Greater Springfield executive officer to retire
Transportation officials discuss $471M Forward 44 initiative
Monday Morning Business Leads: Nov. 16, 2026
Former OMB Bank officer placed on probation
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.